Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses
Abstract
Objective The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. Method Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). Results Ten ( n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]). Conclusion It was possible to generate evidence about the safety profile of different ADHD drugs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous network meta-analyses in ADHD have focused on either children and adolescents or adults only, have typically compared only a few drugs, or have addressed exclusively the safety of treatments.
“Previous network meta-analyses in ADHD have focused on either children and adolescents19, 20, 21, 22, 23, 24 or adults only,25, 26, 27, 28 have typically compared only a few drugs,24, 25, 27, 29 or have addressed exclusively the safety of treatments.26”
Cites
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601 · see citing works
Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions
Evans, D. (2003) · Journal of Clinical Nursing · doi:10.1046/j.1365-2702.2003.00662.x · Cited by 993 · see citing works
Jansen, J. P., & Naci, H. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-159 · Cited by 656 · see citing works
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1147 · Cited by 228 · see citing works
Spencer, T. J., Adler, L. A., Weisler, R. H., & Youcha, S. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0911 · Cited by 79 · see citing works
Adler, L. A., Dirks, B., Deas, P. F., Raychaudhuri, A., Dauphin, M. R., Lasser, R. A., & Weisler, R. H. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08144 · Cited by 62 · see citing works
Bushe, C., Day, K., Reed, V., Karlsdotter, K., Berggren, L., Pitcher, A., Televantou, F., & Haynes, V. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636105 · Cited by 31 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30269-4 · Cited by 1,402 · see citing works
- Authors
- Chierrito de Oliveira, D., Guerrero de Sousa, P., Borges dos Reis, C., Tonin, F. S., Maria Steimbach, L., Virtuoso, S., Fernandez-Llimos, F., Pontarolo, R., & Cristina Conegero Sanches, A.
- Affiliations
- Universidade Estadual do Oeste do Paraná, Cascavel, Brazil
- Universidade Federal do Paraná (BR)
- Universidade Federal do Paraná, Curitiba, Brazil
- Universidade Estadual do Oeste do Paraná (BR)
- Universidade de Lisboa, Lisboa, Portugal
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2017-04-03
- Volume
- 23
- Issue
- 2
- Pages
- 111-120
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2605166492
- Cited by
- 14
- References
- 7
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 2
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Attention Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- adult ADHD, ADHD medication, drug safety, atomoxetine, appetite loss, insomnia, sleepiness, low libido, adverse drug reactions
- MeSH terms
- Atomoxetine Hydrochloride, Network Meta-Analysis, Adult, Amphetamine, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Humans, Sleep Initiation and Maintenance Disorders, Methylphenidate, Wakefulness, Odds Ratio, Databases, Factual, Treatment Outcome, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
